House Republicans are asking Homeland Security Secretary Kristi Noem to explain reports about the Biden administration having purchased a device allegedly linked to "Havana Syndrome." House Homeland ...

Two out of three adults diagnosed with complex regional pain syndrome (CRPS) will experience new or worsening migraines, with one in five patients suffering near-daily headaches. A new study from ...

Children with fragile X syndrome display widespread differences in brain morphology, including larger gray matter volume in subcortical regions and distinct brain-behavior correlations. Children with ...

Mirum Pharmaceuticals MIRM announced that it has enrolled the first patient in the phase II BLOOM study evaluating its newly in-licensed PDE4D inhibitor, MRM-3379, for treating Fragile X syndrome (FXS ...

Fragile X syndrome (FXS), also called Martin-Bell syndrome, is one of the most common cause of inherited intellectual disability. FXS happen because of a change in a gene on the X chromosome. This ...

After its cannabidiol gel candidate failed a phase 3 trial in fragile X syndrome, Harmony Biosciences has now paused development of the asset in a different genetic disease. Harmony announced in ...

New research suggests a missing brain molecule may hold the key to understanding – and potentially treating – the faulty neural circuits seen in Down syndrome. Restoring the molecule, called ...

Harmony Biosciences Holdings, Inc. is downgraded from Buy to Hold after a failed Phase 3 trial for ZYN002 in Fragile X syndrome. HRMY's pipeline setback and sNDA rejection raise concerns about ...

Shares of Harmony Biosciences Holdings, Inc. HRMY lost 16.56% on Sept. 24 after the company announced the failure of the late-stage registrational RECONNECT study on pipeline candidate ZYN002 in ...

Sept 24 (Reuters) - Harmony Biosciences (HRMY.O), opens new tab said on Wednesday its experimental drug for a rare genetic disorder failed to meet the main goal in a late-stage trial, sending its ...